BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25939871)

  • 1. Influence of SLCO1B1 polymorphism on maintenance therapy for childhood leukemia.
    Suzuki R; Fukushima H; Noguchi E; Tsuchida M; Kiyokawa N; Koike K; Ma E; Takahashi H; Kobayashi C; Nakajima-Yamaguchi R; Sakai A; Saito M; Iwabuchi A; Kato K; Nakao T; Yoshimi A; Sumazaki R; Fukushima T
    Pediatr Int; 2015 Aug; 57(4):572-7. PubMed ID: 25939871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy.
    Eldem İ; Yavuz D; Cumaoğullari Ö; İleri T; Ünal İnce E; Ertem M; Doğanay Erdoğan B; Bindak R; Özdağ H; Şatiroğlu-Tufan NL; Uysal LZ
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):e289-e294. PubMed ID: 29683944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
    Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
    Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
    Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Torii C; Sato R; Shimada H; Tanigawara Y; Kosaki K; Takahashi T
    J Pediatr Hematol Oncol; 2008 May; 30(5):347-52. PubMed ID: 18458567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
    Rudin S; Marable M; Huang RS
    Genomics Proteomics Bioinformatics; 2017 Apr; 15(2):82-93. PubMed ID: 28391009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.
    Tanaka Y; Manabe A; Fukushima H; Suzuki R; Nakadate H; Kondoh K; Nakamura K; Koh K; Fukushima T; Tsuchida M; Koike K; Kiyokawa N; Noguchi E; Sumazaki R; Komiyama T
    Pharmacogenomics J; 2015 Aug; 15(4):380-4. PubMed ID: 25403995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
    Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
    Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Combined Presence of Hepatitis C Virus and Polymorphisms in Different Genes With Toxicities of Methotrexate and 6-Mercaptopurine in Children With Acute Lymphoblastic Leukemia.
    Abdelaziz DH; Elhosseiny NM; Khaleel SA; Sabry NA; Attia AS; El-Sayed MH
    Pediatr Blood Cancer; 2016 Sep; 63(9):1539-45. PubMed ID: 27163515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study.
    Reimer T; Kempert S; Gerber B; Thiesen HJ; Hartmann S; Koczan D
    BMC Cancer; 2016 May; 16():337. PubMed ID: 27234217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
    Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
    Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
    Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
    J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Moradveisi B; Muwakkit S; Zamani F; Ghaderi E; Mohammadi E; Zgheib NK
    Front Pharmacol; 2019; 10():916. PubMed ID: 31507415
    [No Abstract]   [Full Text] [Related]  

  • 16. [Association between the methylenetetrahydrofolate reductase gene polymorphisms and haplotype with toxicity response of high dose methotrexate chemotherapy].
    Liao QC; Li XL; Liu ST; Zhang Y; Li TY; Qiu JC
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Jul; 33(7):735-9. PubMed ID: 22968027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
    Tantawy AA; El-Bostany EA; Adly AA; Abou El Asrar M; El-Ghouroury EA; Abdulghaffar EE
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):28-34. PubMed ID: 19923983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
    Stanulla M; Schaeffeler E; Flohr T; Cario G; Schrauder A; Zimmermann M; Welte K; Ludwig WD; Bartram CR; Zanger UM; Eichelbaum M; Schrappe M; Schwab M
    JAMA; 2005 Mar; 293(12):1485-9. PubMed ID: 15784872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
    Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
    Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma.
    Shimasaki N; Mori T; Samejima H; Sato R; Shimada H; Yahagi N; Torii C; Yoshihara H; Tanigawara Y; Takahashi T; Kosaki K
    J Pediatr Hematol Oncol; 2006 Feb; 28(2):64-8. PubMed ID: 16462575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.